Biodexa Pharmaceuticals Reports GBP0.01 Loss Per Share for 2025 Operations
Summary
Biodexa Pharmaceuticals announced a loss of GBP0.01 per share from continuing operations for the full year 2025. This financial update provides a key insight into the company's operational performance and burn rate for the past year. For a micro-cap pharmaceutical company, these results are material for investors evaluating its financial stability and progress, especially following its recent reverse ADR split and the initiation of a global early access program for eRapa. Traders will be looking for more comprehensive financial statements to understand the full context of these results and future outlook.
At the time of this announcement, BDRX was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $409.1K. The 52-week trading range was $0.65 to $19.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.